Trial Profile
Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms DARWIN1
- 28 Nov 2023 Status changed from active, no longer recruiting to completed.
- 22 Feb 2022 Status changed from recruiting to active, no longer recruiting.
- 06 Nov 2018 Planned End Date changed from 1 Jan 2023 to 1 Nov 2023.